Skip to main content
SSO 2026 Annual Meeting Main banner

PSM

CME

The Current Management of Peritoneal Mesothelioma

Thursday, March 5, 2026
8:55 AM - 9:55 AM MST
Location:101A-C
CE: 1

This 60-minute session is designed to demonstrate the current management guidelines of peritoneal mesothelioma and better the learner’s understanding of the association of this disease with its most commonly linked genetic mutation.

Learning Objectives:

  • Discuss selection criteria and technical considerations for CRS/HIPEC.
  • Explore systemic therapy in the neoadjuvant and adjuvant setting for peritoneal mesothelioma.
  • Discuss the role of molecular analysis in developing targeted therapies for this disease process.

Presentations:

  • 8:58 AM - 9:13 AM MST
    Disease Assessment/Histology and Mutational Analysis

    Faculty: Edward A. Levine, MD – Wake Forest University

  • 9:13 AM - 9:16 AM MST
    Q&A
  • 9:16 AM - 9:31 AM MST
    Immune Checkpoint Inhibitors and Systemic Chemotherapy in PM

    Faculty: Laura A. Lambert, MD, FACS – NYU Grossman SOM/NYU Langone Health (Long Island)

  • 9:31 AM - 9:34 AM MST
    Q&A
  • 9:34 AM - 9:49 AM MST
    Building Consortium-based Guidelines for Rare Malignancies – Consensus Guidelines for Peritoneal Mesothelioma

    Faculty: Kiran K. Turaga, MD, MPH (he/him/his) – Yale University

  • 9:49 AM - 9:52 AM MST
    Q&A